Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approval of Intragastric Balloon System
Device assists adults with weight management
Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.
Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.
Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.
Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.
This Week's Must Reads
CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al
USPSTF: Interventions to Prevent Child Maltreatment, JAMA; 2018 Nov 27; US Preventive Services Task Force
Team-Based Primary Care in Chronically Ill Patients, JAMA Intern Med; ePub 2018 Nov 26; Meyers, et al
Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al
PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al
Must Reads in Obesity
Is Obesity Associated With Adverse CV Outcomes?, JAMA Netw Open; 2018 Nov 16; Riaz, et al
Early Antibiotic Use & Weight Outcomes in Children, Pediatrics; ePub 2018 Oct 31; Block, Bailey, et al
Efficacy of Bariatric Procedures for Weight Loss, Ann Intern Med; ePub 2018 Oct 30; Arterburn, et al
Bariatric Surgery & Macrovascular Disease in T2D, JAMA; 2018 Oct 16; Fisher, Johnson, et al
Adverse Childhood Experiences & Weight Status, J Pediatr; ePub 2018 Oct 1; Davis, Barnes, et al